Clinical Trials Logo

HIV Infection Primary clinical trials

View clinical trials related to HIV Infection Primary.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05947266 Enrolling by invitation - Clinical trials for HIV Infection Primary

Intervening With Haitian Immigrants in the U.S. to Improve HIV Outcomes

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test a culturally tailored engagement and retention intervention for Haitian Immigrants Living With HIV (HILWH). The main questions it aims to answer are: - Does this intervention result in measurable engagement and retention in care? - Does this intervention result in measurable viral suppression within 6 months? Participants will - participate in a pilot health intervention entailing 4 individual meetings, approximately once monthly over a six-month period and completing research questionnaires at enrollment, post-intervention and at 6 months post-enrollment. - Six participants who have completed the pilot intervention and agree to take part, will participate in the photovoice portion of the study. This activity will consist of 6 additional meetings where participants will be taught about using photographs to illustrate their experience participating in the study and take and display photographs.

NCT ID: NCT05492565 Enrolling by invitation - Clinical trials for Hepatitis, Viral, Human

Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis

SeVIHPrEP
Start date: January 1, 2020
Phase:
Study type: Observational [Patient Registry]

Pre-exposure prophylaxis (PrEP) based on tenofovir represents a considerably new preventive intervention that has shown to significantly decrease the number of HIV infections while it enables early diagnosis of HIV and other sexually transmitted diseases (STI). In Southern Spain, the target population to receive PrEP are men who have sex with men (MSM) with a history of STI and who pursue high-risk sexual practices regarding the acquisition of HIV, including an elevate number of sex partners, no or inconsistent condom use and the use of specific recreational drugs in the context of sexual activity ("chemsex"). Despite the benefits of PrEP use, it must be taken into consideration that risk compensations that may facilitate the acquisition of other STI may occur, including a higher implementation of risk practices and an increase in the number of partners, which is made easy as various social networks designed for this purpose are available nowadays. In order to better understand the benefit/drawback ratio, accurate data of a population using PrEP under real-life conditions, with densely scheduled follow-up and well-characterized (socio-)demographic parameters, sexual behaviour and STI are warranted.